Chaperonins in disease: mechanisms, models, and treatments

J C Ranford, B Henderson

Chaperonins are oligomeric proteins that assist in the folding of nascent or denatured proteins. Bacterial chaperonins are strongly immunogenic and can cause tissue pathology. They have been implicated in infection, autoimmune disease, and idiopathic or multifactorial diseases, such as arthritis and atherosclerosis. Chaperonin 60 proteins are also involved in prion diseases. In the past few years, much progress has been made in unravelling the involvement of various bacterial and mammalian chaperonin 60 (Cpn 60 or hsp 60) proteins in such diseases, and in proposing mechanisms for their biological actions, although we are still some way from a full understanding of chaperonin action that might lead to immunotherapeutic approaches. This review focuses on the current knowledge of the roles of Cpn 60 in the pathology of infectious and immune diseases, and discusses models for the actions of this molecule. Some potential therapeutic strategies will also be reviewed.

Chaperonins are a subset of the ubiquitous group of proteins known as molecular chaperones. The chaperonins assist in the correct folding of most proteins in the cell under both normal and stress conditions. Group I chaperonins (Cpn 60) are prokaryotic proteins, also found in the mitochondria of eukaryotes. Eukaryotes also possess a cytosolic chaperonin known as CCT (chaperonin containing TCP-1), a group II chaperonin. It is not known whether CCT plays a role in disease; therefore, this review is concerned only with the group I chaperonin, Cpn 60.

Chaperonin assisted folding is achieved by sequestration of the misfolded protein in a hydrophobic environment, away from other proteins, to prevent aggregation. Chaperonins are essential proteins and are found in almost all prokaryotes and eukaryotes. There are few exceptions: to date, the only organisms shown to lack chaperonins are some parasites, such as microsporidia and mycoplasma, which have extremely small genomes.

There are two chaperonin proteins, Cpn 60 and Cpn 10, which work together in an oligomeric assembly to achieve the correct folding of proteins, without being involved in the final protein structure themselves. However, before their role as protein folding molecules was discovered the chaperonins of certain pathogenic bacteria were identified as major immunogens. In recent years, further evidence of the involvement of bacterial chaperonin proteins in many different aspects of infection and immunity has come to light. Mammalian Cpn 60 proteins are also implicated as endogenous stress signals, and are common suspects in current models of autoimmune disease. These aspects of the chaperonins have taken centre stage and are the focus of intensive research efforts in the fields of bacterial infection, idiopathic diseases such as arthritis and atherosclerosis, and autoimmune conditions. Thus, the chaperonins have emerged not only as crucial in the normal functions of the cell, but as having a central role in mammalian defenses against pathogenic attack and the response to damage or stress.

“Chaperonins are essential proteins and are found in almost all prokaryotes and eukaryotes”

In protein folding, Cpn 60 and Cpn 10 work together as parts of the same assembly. However, Cpn 10, being a structurally and functionally different protein, should perhaps more accurately be described as a “co-chaperone”. Both Cpn 60 and Cpn 10 have roles in pathogenesis and immunity; however, Cpn 10 will not be discussed in this review. For a recent review of the involvement of this protein in infection and immunity see Ranford et al.

DEFICIENCY OF CPN 60

Cpn 60 is essential for cell survival and, therefore, there are few instances of disease caused by lack of this protein because these are usually fatal. However, there is a temperature sensitive yeast mutant that has mutations in its cpn60 gene, which result in a single amino acid substitution in the Cpn 60 protein. This mutant displays defects in respiration and in steady state mRNA accumulation that can be alleviated by the addition of wild-type Cpn 60. There have also been a few reports of Cpn 60 deficiency in humans. Huckriede and Agsteribe reported a patient with systemic mitochondrial encephalopathy, which was caused by multiple deficiencies in mitochondrial enzymes. This patient was found to have lower than normal concentrations of Cpn 60.

Abbreviations: CCT, chaperonin containing TCP-1; Cpn, chaperonin; IL-1, interleukin 1; PAMPs, pathogen associated molecular patterns; PrP, prion protein; PrPSc, abnormal, pathogenic isofrom of PrP, TLR, Toll-like receptor

See end of article for authors’ affiliations

Correspondence to:
Dr B Henderson, Cellular Microbiology Research Group, Eastman Dental Institute, University College London, 256 Gray’s Inn Road, London WC1X 8LD, UK, B.Henderson@eastman.ucl.ac.uk

Accepted for publication 5 March 2002
and this was hypothesised to be the cause of the disease. Another Cpn 60 deficient patient presented with congenital lactic acidosaemia, again caused by insufficiency of the mitochondrial enzymes involved in respiration. Neither patient was very long lived, thus demonstrating the crucial requirement for Cpn 60.

**IMMUNE SYSTEM STIMULATION BY CPN 60**

Bacterial Cpn 60 is an important factor in the immune response to many pathogens; in fact, before the identification of “hsp 60” (as it was previously called) as the protein folding homologue of GroEL (the *Escherichia coli* Cpn 60 and the best studied chaperonin), it was known as “common antigen”. It affects both the innate and acquired immune systems, producing antibody and T cell responses, in addition to innate immune responses. As an example, one fifth of reactive T cells in mice infected with Mycobacterium tuberculosis recognise *M. tuberculosis* Cpn 60.2 (previously known as hsp 65). Children immunised with the trivalent diphtheria/pertussis/tetanus vaccine are also found to carry high titres of anti-Cpn 60 antibody, and these authors suggest that priming of the immune system to Cpn 60 is a common phenomenon that occurs very early in life.

On the innate immune system front, Cpn 60 proteins from *E. coli*, *M. tuberculosis*, and *Chlamydia trachomatis* all induce the production of pro-inflammatory cytokines by monocytes. *Escherichia coli* Cpn 60 also directly induces human umbilical vein endothelial cells to produce the adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin, independently of the normal interleukin 1 (IL-1)/tumour necrosis factor α mediated route of induction. These same adhesions were also produced by human vascular epithelium in response to *C. trachomatis* Cpn 60 in a study of atherogenesis. In this study, smooth muscle cells and macrophages also reacted to *C. trachomatis* Cpn 60 by producing cytokines. Bacterial Cpn 60 molecules can also induce fibroblasts and epithelial cells to produce cytokines.

The obvious mechanism by which Cpn 60 might be expected to signal intercellularly is for bacterial or host Cpn 60 to be secreted (or otherwise present outside of the cell), and for a receptor to be present on the surface of certain eukaryotic (host) cell types. There is evidence for both, although reports of extracellular Cpn 60 are controversial. Endogenous Cpn 60 is reported to be expressed on the surface of infected cells, but the mechanism for this transport is unknown. Cpn 60 is a mitochondrial protein, possessing a mitochondrial targeting sequence, and there is as yet no known mechanism by which this protein is exported from the cell. It is possible that extracellular Cpn 60 is not the intact oligomeric chaperonin, but a degraded product released from necrotic or damaged cells.

In vitro, at least, it is clear that exogenous Cpn 60 can bind to cells via specific receptors and cause changes in those cells. There are now several reports of receptors for Cpn 60, including the monocyte specific lipopolysaccharide receptor, CD14, and the Toll-like receptors (TLRs). Furthermore, it was recently reported by Vabulas et al that both human and chlamydial Cpn 60 proteins activate the Toll-IL-1 receptor signalling pathway by binding TLR2 and TLR4. These authors also reported that this activation is dependent on endocytosis of Cpn 60.

“In vitro, at least, it is clear that exogenous Cpn 60 can bind to cells via specific receptors and cause changes in those cells”

It appears then, that there are multiple receptors for Cpn 60. It is probable that heterogeneity of receptor expression and affinity leads to diversity of response, and that this response is integrated with information about other aspects of the environment, such as the presence of other bacterial components or stress signals. Figure 1 shows a suggested model of bacterial Cpn 60 induction of the immune system. Clearly though, this is a controversial area in which more work needs to be carried out, so that the extracellular role of Cpn 60 can be more accurately defined.

**INVOLVEMENT OF CPN 60 IN BONE RESORPTION**

In 1995 it was discovered that Cpn 60 from the oral pathogen *Actinobacillus actinomycetemcomitans* (which is implicated in the pathology of localised juvenile periodontitis, a condition that involves destruction of alveolar bone) is a potent mediator of bone resorption in an in vitro murine calvarial bone model. Interestingly, although *E. coli* Cpn 60 was also active in this model, other bacterial Cpn 60 molecules from *M. tuberculosis* and *M. leprae* were not. Further work revealed that *E. coli* Cpn 60 induces the formation of osteoclasts, the multinucleate myeloid bone resorbing cells.

It is unclear why Cpn 60 molecules from some bacteria stimulate bone resorption whereas others have little or no effect. Differences have also been found in cytokine production by cells that were induced by different Cpn 60s. Thus, it is probable that, despite their apparent high homology, there is sufficient variation in the sequence and/or the structure of these homologous chaperonins to result in differences in biological effects.

**DIVERGENCE IN CHAPERONIN SEQUENCES AND EFFECTS**

The group I chaperonins show extensive sequence similarity with one another; typically around 70%. However, these proteins are not homologous in terms of their effects on cells; a more detailed analysis reveals some important differences. Interestingly, some bacteria, including *M. tuberculosis*, have more than one Cpn 60 protein. During infection, these proteins may have different effects on host cells. For instance, *M. tuberculosis* Cpn 60.1 is a more potent stimulator of monocytes than Cpn 60.2. These two proteins share 76% similarity at the amino acid level, with most of the divergence being at the C-terminus. Thus, it could be that certain residues at the C-terminus, or even individual residues elsewhere within the protein, account for these differences. Even small changes in amino acid sequence can lead to vast alterations in the function of Cpn 60. For example, in a report by Yoshida et al, a single amino acid substitution in *E. coli* Cpn 60 conferred insecticidal toxicity on this protein. Thus, even single amino acid changes can result in large differences in the biological effects of these proteins. This is certainly an aspect of chaperonin research that needs to be investigated because it may provide important clues that could account for the observed differences in immunogenicity between the different proteins.

**INVOLVEMENT OF CPN 60 IN AUTOIMMUNE DISEASE**

It is still not clear whether host immune responses to exogenous chaperonins are protective or damaging, or indeed, both. It is hypothesised that, given the strong sequence conservation of bacterial and human Cpn 60 (for example, *E. coli* and human Cpn 60 protein sequences share 52% identity and 67% similarity at the amino acid level), T cell mediated immune responses mounted by the host to bacterial Cpn 60 may result in crossreactivity to the host Cpn 60, causing an autoimmune reaction. There is increasing evidence of a possible link between bacterial infection and the induction of some autoimmune diseases. For example, self Cpn 60 reactive CD8 T cells were
likely to become pregnant. Result of a previous or ongoing chlamydial infection, were less antibodies that are crossreactive with human Cpn 60. This damage might be caused by antichlamydial cause of infertility, owing to damage or occlusion of the fallopian tubes. This damage might be caused by antichlamydial antibodies to elicit a cell mediated immune response also playing their part. Autoimmunity to Cpn 60 may also be a factor in infertility and fetal/embryo loss. Chlamydial infections are a common cause of infertility, owing to damage or occlusion of the fallopian tubes. This damage might be caused by antichlamydial antibodies that are crossreactive with human Cpn 60. It was found that women undergoing in vitro fertilisation who had IgA in their cervical mucosa to Cpn 60 of C trachomatis, as a result of a previous or ongoing chlamydial infection, were less likely to become pregnant. In another experiment, fertilised mouse embryos that were incubated in maternal sera containing antibodies reactive to mouse Cpn 60 developed less well than those not exposed to such antibodies. The ability of human Cpn 60 to elicit a cell mediated immune response also correlates with early stage pregnancy loss. In a clinical evaluation of factors involved in adverse pregnancy outcome, Cpn 60–antibody complexes were found in the placenta of a high proportion of preterm births. These findings suggest that the crossreactivity of antibodies to human Cpn 60 may be a cause of many difficulties encountered in conception, pregnancy, and birth.

Paradoxically, however, it seems that in some situations Cpn 60 may inhibit or ameliorate the progression of some autoimmune diseases. In a murine model of insulin dependent diabetes mellitus, a Cpn 60 peptide was identified as a target for the T cell clones that were attacking the pancreatic islets. However, the administration of this peptide early in life appeared to prevent the onset of this disease. Administration of Cpn 60 in a rat model of adjuvant arthritis also produces a protective effect, probably through modulation of T cell function.

**PRION DISEASES**

Prions are transmissible elements that are thought to be composed only of protein. The prion protein, PrP, is a host encoded glycoprotein that can exist in an abnormal, pathogenic isomorf known as PrPSc. PrPSc is thought to be the infectious agent. It is hypothesised that PrPSc acts as a template upon which normal cellular PrP, which contains almost no β sheet structure, is induced to convert to the β sheet containing PrPSc isomorf, thus forming fibrillar aggregates that cause disease. Little is known about the mechanism of conversion of the normal PrP protein to the PrPSc isoprotein. However, human Cpn 60, presumably in its “protein folding” role, has been shown to interact specifically with PrPSc in a yeast two hybrid screen. More recently, it has been shown that *E coli*
Cpn 60 actively promotes conversion to the PrP\textsuperscript{Sc} form in vitro.\textsuperscript{11} It is important to note that these results are from in vitro experiments, and there is as yet no evidence that PrP and Cpn 60 can interact in vivo, because they are not known to occur in the same cellular compartments. However, this is clearly a very exciting area of research that has the potential to yield greater understanding of the spongiform encephalopathies and possible therapeutic intervention.

**MODELS OF CPN 60 ACTION**

The current dogma is that the immune system evolved to distinguish between "self" and "non-self". However, the basic self–non-self model fails to explain some aspects of immunity, and it has been modified by Janeway\textsuperscript{12} to include molecules recognised by cells of the innate immune system, in addition to foreign molecules recognised by T and B cells. The molecules that might be recognised by innate immune cells such as macrophages and dendritic cells are common to many bacteria, parasites, and fungi, and could be generically recognised. Such molecules have been termed pathogen associated molecular patterns (PAMPs), and might include—for example, lipopolysaccharide of Gram negative bacteria, mannans such as lipoparabinomannan from mycobacteria, or viral double stranded RNA. Given their ubiquitous nature and high interspecies homology, and because it has now been reported that chaperonin proteins are found extracellularly, these proteins are another possible candidate for PAMPs.

"Cpn 60 is ideally placed to play a central role in the initiation of the host immune response, whatever the actual nature of the immune system"

The idea of chaperonins as initiators of immune responses also fits in increasingly well, but in a different way, with another model of the immune system: the “danger” model.\textsuperscript{13} This idea proposes that, instead of the major function of the immune system being to discriminate between self and non-self, its function is actually to recognise "danger"; specifically, certain “danger signals” that emanate from the tissues of the body, rather than from pathogens. Thus, molecules released from stressed, damaged, and necrotic host cells would be seen by the immune system as signals of infection or wounding, and the appropriate response would be mounted. In this model, it is self Cpn 60 that is being recognised, not the Cpn 60 of the pathogen. Heat shock proteins such as Cpn 60 might be a good example of a danger signal, because they are themselves induced by stress or damage and would be present in large amounts in tissue containing stressed, damaged, or lysed cells. Thus, it would seem that Cpn 60 is ideally placed to play a central role in the initiation of the host immune response, whatever the actual nature of the immune system.

**THERAPEUTIC POSSIBILITIES**

There is still much to be learned about the roles of chaperonins in pathology and the immune system and, given their diverse effects, at this stage it might seem rather premature to consider their use in prophylaxis or treatment. However, as detailed earlier, there are already examples of the protective effect of immunisation with Cpn 60 or specific Cpn 60 peptides in animal models of autoimmune disease.\textsuperscript{4, 5} The crossreactivity with human Cpn 60, seen in many autoimmune diseases, suggests that early tolerisation to the protein by immunisation might protect against the development of pathology.

The inflammatory effects of the chaperonins caused by their cytokine stimulatory action could theoretically be ameliorated by the use of anti-Cpn 60 antibodies, particularly antibodies that do not crossreact with human Cpn 60. However, the problem with all these potential treatments is that Cpn 60 seems to have diverse and complex functions in the immune system, and this might lead to unforeseen effects of treatment. The task ahead is to identify the benefits and risks of such intervention. There is greater potential at the present time, for Cpn 60 related treatments to specific diseases, rather than a cure all approach. Doubtless, as our knowledge and understanding of the role of Cpn 60 in infection and immunity grows, we will be more able to predict and treat many currently disabling and life threatening diseases, to gain more insight into this biologically and medically fascinating molecule.

**ACKNOWLEDGEMENTS**

The authors thank S Nair for critical evaluation of the manuscript. We thank the BBBSRC, the Arthritis Research Campaign, and the British Heart Foundation for funding.

**REFERENCES**

Call for peer reviewers

Clinical Evidence is a regularly updated evidence based journal available worldwide both as a paper version and on the internet. Clinical Evidence urgently needs to recruit a number of new contributors. Contributors are health care professionals or epidemiologists with experience in evidence based medicine and the ability to write in a concise and structured way.

Clinical Evidence needs to recruit a number of new peer reviewers. Peer reviewers are health care professionals or epidemiologists with experience in evidence based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity and accessibility of specific topics within the journal and their usefulness to the intended audience (international generalists and health care professionals, possibly with limited statistical knowledge). Topics are usually 2000–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicaledvidence.com and contact Polly Brown (pbrown@bmjgroup.com).